NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY)’s stock price was down 10.2% on Tuesday . The stock traded as low as $0.75 and last traded at $0.82, approximately 2,392,064 shares were traded during trading. An increase of 91% from the average daily volume of 1,252,650 shares. The stock had previously closed at $0.91.

Separately, Zacks Investment Research cut NovaBay Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th.

The stock’s fifty day simple moving average is $0.68.

A hedge fund recently raised its stake in NovaBay Pharmaceuticals stock. Virtu Financial LLC boosted its stake in shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) by 127.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 71,169 shares of the biopharmaceutical company’s stock after acquiring an additional 39,878 shares during the period. Virtu Financial LLC owned about 0.26% of NovaBay Pharmaceuticals worth $46,000 at the end of the most recent quarter.

About NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.

See Also: What is the Dividend Aristocrat Index?

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.